Stem-cell transplants show limited benefit for double-hit lymphoma patients in remission

(University of Pennsylvania School of Medicine) Patients with double hit lymphoma (DHL) who undergo autologous stem-cell transplantation (autoSCT) after achieving remission are not more likely to remain in remission or live longer than patients who do not undergo autoSCT, according to a new analysis from the Perelman School of Medicine and the Abramson Cancer Center of the University of Pennsylvania.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news